Lindsey Shapiro, PhD, science writer —

Lindsey earned her PhD in neuroscience from Emory University in Atlanta, where she studied novel therapeutic strategies for treatment-resistant forms of epilepsy. She was awarded a fellowship from the American Epilepsy Society in 2019 for this research. Lindsey also previously worked as a postdoctoral researcher, studying the role of inflammation in epilepsy and Alzheimer’s disease.

Articles by Lindsey Shapiro

Acthar Gel may be cost-effective for treating pulmonary sarcoidosis

Acthar Gel (repository corticotropin injection) may be a cost-effective approach relative to standard-of-care glucocorticoid therapy for adults with advanced active pulmonary sarcoidosis. That’s according to an analysis done by the therapy’s developer Mallinckrodt Pharmaceuticals, which found that “the initial high cost of Acthar Gel treatment for sarcoidosis…

XTMAB-16 wins orphan drug status in Europe; Phase 1/2 trial begins

The European Medicines Agency (EMA) has granted XTMAB-16, Xentria‘s investigational antibody therapy, orphan drug designation for sarcoidosis. The status is intended to help speed the development of therapies that would fulfill an unmet health need for people with life-threatening or chronically debilitating rare diseases, which are defined as…